A LeMaitre Vascular (LMAT) Insider Sold 2,625 Shares for $285K

1 hour ago 2

Cory Renauer, The Motley Fool

Sat, March 28, 2026 astatine 8:37 AM CDT 4 min read

On March 11, 2026, LeMaitre Vascular (NASDAQ:LMAT) Senior Vice President, Operations, Trent G Kamke, reported the workout and contiguous merchantability of 2,625 shares of communal banal for full proceeds of astir $285,000, according to this SEC Form 4 filing.

Metric

Value

Context

Shares sold (direct)	2,625	Open-market shares sold (code 'S') successful this filing
Transaction value	$284,812.50	Based connected SEC Form 4 weighted mean acquisition terms ($108.50)
Post-transaction shares (direct)	6,677	Directly held shares aft transaction completion
Post-transaction worth (direct ownership)	~$722,000	Based connected March 11, 2026 marketplace close

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($108.50); post-transaction worth based connected March 11, 2026, marketplace close.

What was the operation and rationale for the transaction?
The commercialized reflects an workout of 2,625 vested options instantly followed by a nonstop merchantability of the communal shares, a communal mechanics for executives to monetize equity awards portion maintaining compliance with institution trading policies.
How did this transaction interaction Kamke's ownership stake?
Direct communal banal holdings decreased from astir 9,000 shares to 6,677 shares, marking a 28.22% simplification successful nonstop equity exposure; nary indirect holdings were progressive oregon stay post-transaction.
How does the commercialized acceptable wrong Kamke's caller activity?
This transaction matches the caller period's median merchantability size (2,625 shares) and percent of holdings sold per commercialized (28.22%), indicating consistency successful liquidation cadence arsenic disposable nonstop holdings person declined implicit time.
What continuing equity vulnerability does Kamke retain?
Kamke continues to clasp 1,353 straight owned banal options, which tin beryllium exercised for further communal shares successful the future, preserving imaginable upside alignment with institution performance.

Metric

Value

Revenue (TTM)	$249.6 million
Net income (TTM)	$57.7 million
Dividend yield	0.99%
1-year terms change	32.90%

* 1-year terms alteration calculated utilizing March 11, 2026, arsenic the notation date.

Offers a portfolio of aesculapian devices and implants for the attraction of peripheral vascular disease, including angioscopes, embolectomy and thrombectomy catheters, carotid shunts, vascular grafts, and closure systems.
Generates gross chiefly done nonstop income and distributor relationships, focusing connected proprietary vascular products designed for surgical involution and vascular repair.
Serves hospitals, surgeons, and healthcare providers treating vascular disease, with a planetary lawsuit basal spanning North America, Europe, and different planetary markets.

Read Entire Article